70639727b6
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Pipeline auto-fixer: removed [[ ]] brackets from links that don't resolve to existing claims in the knowledge base.
80 lines
6.5 KiB
Markdown
80 lines
6.5 KiB
Markdown
---
|
|
type: source
|
|
title: "VigiBase Pharmacovigilance: GLP-1 Shows Disproportionate Reporting for Depressed Mood (aROR 1.70) and Suicidality (1.45) Despite Protective Cohort Evidence"
|
|
author: "ScienceDirect / Clinical Nutrition (VigiBase study team)"
|
|
url: https://www.sciencedirect.com/science/article/pii/S0261561425001657
|
|
date: 2025-12-01
|
|
domain: health
|
|
secondary_domains: []
|
|
format: research-article
|
|
status: unprocessed
|
|
priority: medium
|
|
tags: [GLP-1, semaglutide, psychiatric-safety, pharmacovigilance, vigibase, adverse-events, depression, suicidality, eating-disorders]
|
|
intake_tier: research-task
|
|
---
|
|
|
|
## Content
|
|
|
|
**Study:** "Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: A VigiBase study." Published in ScienceDirect (2025, data through December 1, 2024).
|
|
|
|
**Method:** Disproportionality analysis of WHO VigiBase (global adverse event reports database). Analyzed spontaneous adverse event reports for semaglutide, dulaglutide, and liraglutide. Calculated adjusted reporting odds ratios (aROR) for psychiatric outcomes.
|
|
|
|
**Key findings:**
|
|
- Depressed mood disorders: aROR 1.70 (semaglutide) — significant
|
|
- Suicidality: aROR 1.45 (semaglutide) — significant
|
|
- Anxiety: aROR 1.26 (semaglutide) — significant
|
|
- Eating disorders: aROR 4.17-6.80 across all three GLP-1 RAs — HIGHLY significant
|
|
- Only semaglutide showed signals in BOTH FAERS and VigiBase for depression (FAERS: ROR 1.26; VigiBase: ROR 1.38)
|
|
- Liraglutide and tirzepatide showed NO significant depressive disorder signals
|
|
|
|
**Signal context:**
|
|
- Pharmacovigilance reporting signals are NOT incidence estimates — they measure disproportionate reporting relative to other drugs, not absolute risk
|
|
- Notoriety bias: once media covers GLP-1 and depression/suicidality, reporting rates increase independent of causation
|
|
- The Swedish national cohort (n=95,490) uses causal inference methods and shows PROTECTIVE effects for semaglutide on depression/anxiety
|
|
- These two bodies of evidence appear contradictory but are measuring different things
|
|
|
|
**Critical finding — eating disorders:**
|
|
- aROR 4.17-6.80 for ALL THREE GLP-1 RAs studied
|
|
- This signal appears across drugs, not just semaglutide — suggests it's a class effect
|
|
- GLP-1-induced nausea, appetite suppression, and food aversion may trigger eating disorder pathology in susceptible individuals
|
|
- This is the MOST ACTIONABLE safety signal — higher magnitude than depression/suicidality
|
|
|
|
**Concurrent prescribing interaction:**
|
|
- Concurrent antidepressants: OR 4.45 for suicidal ideation reports
|
|
- Concurrent benzodiazepines: OR 4.07 for suicidal ideation reports
|
|
- These interaction signals suggest the highest-risk patients are those with pre-existing psychiatric pharmacotherapy
|
|
|
|
**Regulatory context:**
|
|
- FDA recommends close monitoring for mood changes, emerging/worsening depression, or suicidal behavior during liraglutide and semaglutide treatment
|
|
- FDA review (2023-2024) found NO causal evidence linking GLP-1s to suicidality in clinical trial data
|
|
- EMA monitoring continues
|
|
|
|
**Methodological limitation for interpretation:**
|
|
- All patients with "psychiatric instability" are typically excluded from GLP-1 trials — the highest-risk patients are not represented in clinical trial safety data
|
|
- Real-world pharmacovigilance thus captures a broader population than trials, but is susceptible to reporting bias
|
|
- Indication bias is irreducible in voluntary adverse event reporting
|
|
|
|
## Agent Notes
|
|
|
|
**Why this matters:** This is the "other side" of the GLP-1 psychiatric safety debate. While the Lancet Psychiatry Swedish cohort shows 44% reduced depression risk, the VigiBase signals show semaglutide-specific disproportionate reporting for psychiatric adverse events. The eating disorder signal (aROR 4-7) is most actionable — it's consistent across drug class and magnitude suggests a real class effect rather than reporting artifact.
|
|
|
|
**What surprised me:** The eating disorder signal magnitude (aROR 4.17-6.80) is dramatically higher than the depression/suicidality signals. GLP-1's appetite-suppressing mechanism may precipitate eating disorders in vulnerable individuals — this is the opposite of the anorexia treatment narrative, but makes mechanistic sense. The drug industry doesn't have strong incentives to study this.
|
|
|
|
**What I expected but didn't find:** A clear regulatory response to the eating disorder signal. The FDA focused on suicidality (major media/political attention) but the eating disorder signal appears more consistent and higher-magnitude.
|
|
|
|
**KB connections:**
|
|
- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — safety signal monitoring as market risk
|
|
- Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic — GLP-1 addresses food reward pathways; eating disorder risk in vulnerable individuals is the mechanistic flip side
|
|
|
|
**Extraction hints:**
|
|
1. No standalone claim yet — the evidence is too contradictory to write with confidence
|
|
2. This belongs as a "challenges considered" section in any GLP-1 psychiatric protective claim
|
|
3. The eating disorder signal (aROR 4-7) may eventually warrant its own claim: "GLP-1 receptor agonists carry a class-effect eating disorder risk in vulnerable individuals that is not captured in metabolic disease clinical trials"
|
|
4. Extractor should pair this with the Lancet Psychiatry Swedish study archive to capture the full evidence landscape
|
|
|
|
**Context:** Novo Nordisk semaglutide MDD program interim data expected late 2026 — this will be the decisive evidence on the depression question. The pharmacovigilance signals will be re-evaluated against MDD RCT results.
|
|
|
|
## Curator Notes (structured handoff for extractor)
|
|
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
|
WHY ARCHIVED: Critical counter-evidence to the Swedish cohort protective finding. The eating disorder signal is the most actionable, highest-magnitude psychiatric safety concern from GLP-1s — not adequately covered in current KB.
|
|
EXTRACTION HINT: Pair with the Lancet Psychiatry Swedish cohort archive. The combined picture is: GLP-1 appears protective for worsening depression/anxiety in metabolic patients, but carries class-effect eating disorder risk. These are not contradictory claims — they cover different populations and outcomes.
|